Isto Gets Go-Ahead for Clinical Study of NuQu
ISTO Technologies has received FDA approval to begin a Phase I clinical study for NuQu, an injectable formulation of juvenile cartilage cells designed to treat chronic back pain caused by degenerative disc disease.